ID   NLRP6_HUMAN             Reviewed;         892 AA.
AC   P59044; A8K9F3; E9PJZ8;
DT   19-OCT-2002, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 2.
DT   28-JUN-2023, entry version 175.
DE   RecName: Full=NACHT, LRR and PYD domains-containing protein 6 {ECO:0000305};
DE   AltName: Full=Angiotensin II/vasopressin receptor {ECO:0000250|UniProtKB:Q91WS2};
DE   AltName: Full=PYRIN-containing APAF1-like protein 5 {ECO:0000303|PubMed:12019269};
GN   Name=NLRP6 {ECO:0000303|PubMed:21088234, ECO:0000312|HGNC:HGNC:22944};
GN   Synonyms=NALP6 {ECO:0000303|PubMed:12563287}, PYPAF5
GN   {ECO:0000303|PubMed:12019269};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS LEU-163 AND PHE-361.
RX   PubMed=12019269; DOI=10.1074/jbc.m203915200;
RA   Wang L., Manji G.A., Grenier J.M., Al-Garawi A., Merriam S., Lora J.M.,
RA   Geddes B.J., Briskin M., DiStefano P.S., Bertin J.;
RT   "PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates
RT   activation of NF-kappa B and caspase-1-dependent cytokine processing.";
RL   J. Biol. Chem. 277:29874-29880(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS LEU-163 AND PHE-361.
RX   PubMed=12563287; DOI=10.1038/nrm1019;
RA   Tschopp J., Martinon F., Burns K.;
RT   "NALPs: a novel protein family involved in inflammation.";
RL   Nat. Rev. Mol. Cell Biol. 4:95-104(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS LEU-163
RP   AND PHE-361.
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   FUNCTION, INVOLVEMENT IN INFLAMMASOME COMPLEX, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=12387869; DOI=10.1016/s0014-5793(02)03416-6;
RA   Grenier J.M., Wang L., Manji G.A., Huang W.-J., Al-Garawi A., Kelly R.,
RA   Carlson A., Merriam S., Lora J.M., Briskin M., DiStefano P.S., Bertin J.;
RT   "Functional screening of five PYPAF family members identifies PYPAF5 as a
RT   novel regulator of NF-kappaB and caspase-1.";
RL   FEBS Lett. 530:73-78(2002).
RN   [6]
RP   INDUCTION BY ROSIGLITAZONE.
RX   PubMed=21088234; DOI=10.1152/ajpgi.00397.2010;
RA   Kempster S.L., Belteki G., Forhead A.J., Fowden A.L., Catalano R.D.,
RA   Lam B.Y., McFarlane I., Charnock-Jones D.S., Smith G.C.;
RT   "Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in
RT   mammalian intestine.";
RL   Am. J. Physiol. 300:G253-G263(2011).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=21593405; DOI=10.1073/pnas.1100981108;
RA   Normand S., Delanoye-Crespin A., Bressenot A., Huot L., Grandjean T.,
RA   Peyrin-Biroulet L., Lemoine Y., Hot D., Chamaillard M.;
RT   "Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls
RT   epithelial self-renewal and colorectal carcinogenesis upon injury.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:9601-9606(2011).
RN   [8]
RP   INDUCTION BY CRH AND ROSIGLITAZONE.
RX   PubMed=23470617; DOI=10.1053/j.gastro.2013.02.038;
RA   Sun Y., Zhang M., Chen C.C., Gillilland M. III, Sun X., El-Zaatari M.,
RA   Huffnagle G.B., Young V.B., Zhang J., Hong S.C., Chang Y.M., Gumucio D.L.,
RA   Owyang C., Kao J.Y.;
RT   "Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome
RT   inhibition and transmissible enteritis in mice.";
RL   Gastroenterology 144:1478-1487(2013).
RN   [9]
RP   FUNCTION.
RX   PubMed=30392956; DOI=10.1016/j.cell.2018.09.047;
RA   Hara H., Seregin S.S., Yang D., Fukase K., Chamaillard M., Alnemri E.S.,
RA   Inohara N., Chen G.Y., Nunez G.;
RT   "The NLRP6 inflammasome recognizes lipoteichoic acid and regulates Gram-
RT   positive pathogen infection.";
RL   Cell 175:1651-1664(2018).
RN   [10]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=31932628; DOI=10.1038/s41598-019-57043-0;
RA   Leng F., Yin H., Qin S., Zhang K., Guan Y., Fang R., Wang H., Li G.,
RA   Jiang Z., Sun F., Wang D.C., Xie C.;
RT   "NLRP6 self-assembles into a linear molecular platform following LPS
RT   binding and ATP stimulation.";
RL   Sci. Rep. 10:198-198(2020).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, DOMAIN, INTERACTION WITH PYCARD, AND
RP   MUTAGENESIS OF 352-LYS--LYS-356.
RX   PubMed=34678144; DOI=10.1016/j.cell.2021.09.032;
RA   Shen C., Li R., Negro R., Cheng J., Vora S.M., Fu T.M., Wang A., He K.,
RA   Andreeva L., Gao P., Tian Z., Flavell R.A., Zhu S., Wu H.;
RT   "Phase separation drives RNA virus-induced activation of the NLRP6
RT   inflammasome.";
RL   Cell 184:5759-5774(2021).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH DHX15.
RX   PubMed=34161762; DOI=10.1016/j.celrep.2021.109205;
RA   Xing J., Zhou X., Fang M., Zhang E., Minze L.J., Zhang Z.;
RT   "DHX15 is required to control RNA virus-induced intestinal inflammation.";
RL   Cell Rep. 35:109205-109205(2021).
RN   [13]
RP   FUNCTION.
RX   PubMed=33377178; DOI=10.1111/iej.13469;
RA   Tian X.X., Li R., Liu C., Liu F., Yang L.J., Wang S.P., Wang C.L.;
RT   "NLRP6-caspase 4 inflammasome activation in response to cariogenic
RT   bacterial lipoteichoic acid in human dental pulp inflammation.";
RL   Int. Endod. J. 54:916-925(2021).
RN   [14] {ECO:0007744|PDB:6NCV, ECO:0007744|PDB:6NDJ}
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 14-106, FUNCTION, SUBCELLULAR
RP   LOCATION, SUBUNIT, AND MUTAGENESIS OF LEU-21; LEU-23; 27-GLU-GLU-28;
RP   HIS-39; ARG-42; TRP-53; PHE-71 AND ARG-87.
RX   PubMed=30674671; DOI=10.1073/pnas.1817221116;
RA   Shen C., Lu A., Xie W.J., Ruan J., Negro R., Egelman E.H., Fu T.M., Wu H.;
RT   "Molecular mechanism for NLRP6 inflammasome assembly and activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 116:2052-2057(2019).
RN   [15]
RP   VARIANT VAL-713.
RX   PubMed=26282398; DOI=10.1186/s13023-015-0316-8;
RA   Dahmani M., Ammar-Khodja F., Bonnet C., Lefevre G.M., Hardelin J.P.,
RA   Ibrahim H., Mallek Z., Petit C.;
RT   "EPS8L2 is a new causal gene for childhood onset autosomal recessive
RT   progressive hearing loss.";
RL   Orphanet J. Rare Dis. 10:96-96(2015).
CC   -!- FUNCTION: Acts as the sensor component of the NLRP6 inflammasome, which
CC       mediates inflammasome activation in response to various pathogen-
CC       associated signals, leading to maturation and secretion of IL1B and
CC       IL18 (PubMed:30392956, PubMed:34678144). Inflammasomes are
CC       supramolecular complexes that assemble in the cytosol in response to
CC       pathogens and other damage-associated signals and play critical roles
CC       in innate immunity and inflammation (PubMed:30674671). Acts as a
CC       recognition receptor (PRR): recognizes and binds specific pathogens and
CC       other damage-associated signals, such as lipoteichoic acid (LTA), a
CC       cell-wall component of Gram-positive bacteria, or double stranded RNA
CC       (dsRNA) (PubMed:30392956, PubMed:34678144, PubMed:33377178). May also
CC       recognize and bind lipopolysaccharide (LPS), a major component of the
CC       outer membrane of Gram-negative bacteria; however, LPS is probably not
CC       a major activator of the NLRP6 inflammasome (PubMed:31932628,
CC       PubMed:34678144). Following LTA- or dsRNA-binding, NLRP6 undergoes
CC       liquid-liquid phase separation (LLPS), enhancing multivalent
CC       interactions, an essential step for the formation of the NLRP6
CC       inflammasome polymeric complex (PubMed:34678144). The NLRP6
CC       inflammasome acts by promoting recruitment of effector pro-inflammatory
CC       caspases (CASP1 and/or CASP4) that catalyze maturation and secretion of
CC       IL1B and IL18 in the extracellular milieu (PubMed:30674671,
CC       PubMed:12387869, PubMed:30392956, PubMed:34678144). The NLRP6
CC       inflammasome plays a central role in the maintenance of epithelial
CC       integrity and host defense against microbial infections in the
CC       intestine (PubMed:30392956). Required to restrict infection against
CC       Gram-positive bacteria by recognizing lipoteichoic acid (LTA), leading
CC       to recruitment of CASP4 and CASP1, and subsequent maturation and
CC       secretion of IL1B and IL18 (PubMed:30392956, PubMed:33377178). Involved
CC       in intestinal antiviral innate immunity together with DHX15: recognizes
CC       and binds viral dsRNA to restrict infection by enteric viruses through
CC       the interferon pathway and GSDMD-dependent release of IL18
CC       (PubMed:34678144, PubMed:34161762). Required to prevent infection by
CC       the apicomplexan parasite Cryptosporidium in enterocytes by promoting
CC       GSDMD-dependent release of IL18 (By similarity). The NLRP6 inflammasome
CC       may also regulate the gut microbiota composition by acting as a sensor
CC       of microbiota-associated metabolites to form a PYCARD/ASC-dependent
CC       inflammasome for downstream IL18 release and secretion of antimicrobial
CC       peptides (By similarity). Essential for gut mucosal self-renewal and
CC       proliferation (By similarity). Regulate mucus secretion in an
CC       inflammasome- and autophagy-dependent manner to prevent invasion by
CC       enteric bacteria, (By similarity). During systemic bacterial
CC       infections, the NLRP6 inflammasome negatively regulates neutrophil
CC       recruitment and neutrophil extracellular traps (NETs) formation (By
CC       similarity). May promote peripheral nerve recovery following injury via
CC       an inflammasome-independent mechanism (By similarity).
CC       {ECO:0000250|UniProtKB:Q91WS2, ECO:0000269|PubMed:12387869,
CC       ECO:0000269|PubMed:30392956, ECO:0000269|PubMed:30674671,
CC       ECO:0000269|PubMed:31932628, ECO:0000269|PubMed:33377178,
CC       ECO:0000269|PubMed:34161762, ECO:0000269|PubMed:34678144}.
CC   -!- SUBUNIT: Homomultimer; forms the NLRP6 inflammasome polymeric complex,
CC       a filament composed of homopolymers in response to pathogens and other
CC       damage-associated signals (PubMed:31932628, PubMed:34678144,
CC       PubMed:30674671). The core of NLRP6 inflammasomes consists of a signal
CC       sensor component (NLRP6), an adapter (PYCARD/ASC), which recruits
CC       effector pro-inflammatory caspases (CASP1 and CASP4) (PubMed:34678144,
CC       PubMed:30674671). Interacts (via pyrin domain) with PYCARD/ASC (via
CC       pyrin domain); interaction takes place following NLRP6 activation and
CC       formation of liquid-liquid phase separation (LLPS), initiating
CC       nucleation which greatly enhances further addition of soluble
CC       PYCARD/ASC molecules to the speck in a prion-like polymerization
CC       process (PubMed:34678144, PubMed:30674671). Clustered PYCARD/ASC
CC       nucleates the formation of CASP1 (or possibly CASP4) filaments through
CC       the interaction of their respective CARD domains, acting as a platform
CC       for CASP1 polymerization (PubMed:34678144). CASP1 filament formation
CC       increases local enzyme concentration, resulting in trans-autocleavage
CC       and activation (PubMed:34678144). Active CASP1 then processes IL1B and
CC       IL18 precursors, leading to the release of mature cytokines in the
CC       extracellular milieu and inflammatory response (PubMed:34678144).
CC       Interacts with DHX15 (PubMed:34161762). {ECO:0000269|PubMed:30674671,
CC       ECO:0000269|PubMed:31932628, ECO:0000269|PubMed:34161762,
CC       ECO:0000269|PubMed:34678144}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:12387869,
CC       ECO:0000269|PubMed:31932628}. Inflammasome
CC       {ECO:0000269|PubMed:12387869, ECO:0000269|PubMed:30674671,
CC       ECO:0000269|PubMed:31932628, ECO:0000269|PubMed:34678144}. Cell
CC       membrane {ECO:0000250|UniProtKB:Q63035}. Nucleus membrane
CC       {ECO:0000250|UniProtKB:Q63035}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P59044-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P59044-2; Sequence=VSP_054400;
CC   -!- TISSUE SPECIFICITY: Expressed in peripheral blood leukocytes,
CC       predominantly in granulocytes and, at lower levels, in CD4(+) and
CC       CD8(+) T-cells (PubMed:12387869). Expressed in colonic myofibroblasts
CC       (at protein level) (PubMed:21593405). {ECO:0000269|PubMed:12387869,
CC       ECO:0000269|PubMed:21593405}.
CC   -!- INDUCTION: Up-regulated by rosiglitazone, a PPARG agonist, in Caco2 and
CC       HCT116 colorectal carcinoma cells (PubMed:21088234, PubMed:23470617).
CC       Down-regulated by CRH (at protein level) (PubMed:23470617).
CC       {ECO:0000269|PubMed:21088234, ECO:0000269|PubMed:23470617}.
CC   -!- DOMAIN: The poly-Lys disordered region (352-356) mediates the formation
CC       of liquid-liquid phase separation (LLPS), an essential step for
CC       nucleation and formation of the NLRP6 inflammasome complex.
CC       {ECO:0000269|PubMed:34678144}.
CC   -!- PTM: Polyubiquitinated with 'Lys-63'-linked chains, promoting the
CC       interaction with PYCARD/ASC and formation of the NLRP6 inflammasome.
CC       Deubiquitination by CYLD decreases the interaction with PYCARD/ASC.
CC       {ECO:0000250|UniProtKB:Q91WS2}.
CC   -!- SIMILARITY: Belongs to the NLRP family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF479748; AAL87105.1; -; mRNA.
DR   EMBL; AY154461; AAO18157.1; -; mRNA.
DR   EMBL; AK292668; BAF85357.1; -; mRNA.
DR   EMBL; AC136475; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS60680.1; -. [P59044-2]
DR   CCDS; CCDS7693.1; -. [P59044-1]
DR   RefSeq; NP_001263629.1; NM_001276700.1. [P59044-2]
DR   RefSeq; NP_612202.2; NM_138329.2. [P59044-1]
DR   PDB; 6NCV; EM; 3.70 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/V=1-106.
DR   PDB; 6NDJ; X-ray; 2.27 A; A/B=14-106.
DR   PDBsum; 6NCV; -.
DR   PDBsum; 6NDJ; -.
DR   AlphaFoldDB; P59044; -.
DR   SMR; P59044; -.
DR   BioGRID; 128114; 3.
DR   STRING; 9606.ENSP00000309767; -.
DR   iPTMnet; P59044; -.
DR   PhosphoSitePlus; P59044; -.
DR   BioMuta; NLRP6; -.
DR   DMDM; 259016285; -.
DR   MassIVE; P59044; -.
DR   PaxDb; P59044; -.
DR   PeptideAtlas; P59044; -.
DR   ProteomicsDB; 21300; -.
DR   ProteomicsDB; 57113; -. [P59044-1]
DR   Antibodypedia; 58845; 261 antibodies from 30 providers.
DR   DNASU; 171389; -.
DR   Ensembl; ENST00000312165.5; ENSP00000309767.4; ENSG00000174885.13. [P59044-1]
DR   Ensembl; ENST00000534750.6; ENSP00000433617.1; ENSG00000174885.13. [P59044-2]
DR   GeneID; 171389; -.
DR   KEGG; hsa:171389; -.
DR   MANE-Select; ENST00000534750.6; ENSP00000433617.1; NM_001276700.2; NP_001263629.1. [P59044-2]
DR   UCSC; uc010qvs.4; human. [P59044-1]
DR   AGR; HGNC:22944; -.
DR   CTD; 171389; -.
DR   DisGeNET; 171389; -.
DR   GeneCards; NLRP6; -.
DR   HGNC; HGNC:22944; NLRP6.
DR   HPA; ENSG00000174885; Tissue enriched (intestine).
DR   MIM; 609650; gene.
DR   neXtProt; NX_P59044; -.
DR   OpenTargets; ENSG00000174885; -.
DR   PharmGKB; PA162398002; -.
DR   VEuPathDB; HostDB:ENSG00000174885; -.
DR   eggNOG; ENOG502SANB; Eukaryota.
DR   GeneTree; ENSGT00940000162758; -.
DR   HOGENOM; CLU_002274_2_2_1; -.
DR   InParanoid; P59044; -.
DR   OMA; FMDQSFQ; -.
DR   OrthoDB; 55870at2759; -.
DR   PhylomeDB; P59044; -.
DR   PathwayCommons; P59044; -.
DR   BioGRID-ORCS; 171389; 8 hits in 1150 CRISPR screens.
DR   GeneWiki; NLRP6; -.
DR   GenomeRNAi; 171389; -.
DR   Pharos; P59044; Tbio.
DR   PRO; PR:P59044; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P59044; protein.
DR   Bgee; ENSG00000174885; Expressed in small intestine Peyer's patch and 75 other tissues.
DR   Genevisible; P59044; HS.
DR   GO; GO:0061702; C:canonical inflammasome complex; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0140738; C:NLRP6 inflammasome complex; IDA:UniProtKB.
DR   GO; GO:0043228; C:non-membrane-bounded organelle; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:UniProtKB.
DR   GO; GO:0001530; F:lipopolysaccharide binding; IDA:UniProtKB.
DR   GO; GO:0070891; F:lipoteichoic acid binding; IDA:UniProtKB.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB.
DR   GO; GO:0140677; F:molecular function activator activity; IDA:UniProt.
DR   GO; GO:0038187; F:pattern recognition receptor activity; IDA:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; IBA:GO_Central.
DR   GO; GO:0035591; F:signaling adaptor activity; IDA:UniProt.
DR   GO; GO:0030546; F:signaling receptor activator activity; IDA:UniProt.
DR   GO; GO:0005000; F:vasopressin receptor activity; ISS:UniProtKB.
DR   GO; GO:0097202; P:activation of cysteine-type endopeptidase activity; IEA:Ensembl.
DR   GO; GO:0002526; P:acute inflammatory response; IBA:GO_Central.
DR   GO; GO:0002438; P:acute inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0140374; P:antiviral innate immune response; IDA:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IDA:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0048874; P:host-mediated regulation of intestinal microbiota composition; IEA:Ensembl.
DR   GO; GO:0070266; P:necroptotic process; IEA:Ensembl.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0032689; P:negative regulation of type II interferon production; IEA:Ensembl.
DR   GO; GO:0070946; P:neutrophil-mediated killing of gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0140739; P:NLRP6 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IDA:UniProtKB.
DR   GO; GO:2000494; P:positive regulation of interleukin-18-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0070269; P:pyroptosis; IEA:Ensembl.
DR   GO; GO:0010506; P:regulation of autophagy; IEA:Ensembl.
DR   GO; GO:0050727; P:regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0070255; P:regulation of mucus secretion; IEA:Ensembl.
DR   GO; GO:0009617; P:response to bacterium; IBA:GO_Central.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   CDD; cd08321; Pyrin_ASC-like; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1.
DR   InterPro; IPR004020; DAPIN.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR041267; NLRP_HD2.
DR   InterPro; IPR041075; NOD2_WH.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR45690; NACHT, LRR AND PYD DOMAINS-CONTAINING PROTEIN 12; 1.
DR   PANTHER; PTHR45690:SF1; NACHT, LRR AND PYD DOMAINS-CONTAINING PROTEIN 6; 1.
DR   Pfam; PF05729; NACHT; 1.
DR   Pfam; PF17776; NLRC4_HD2; 1.
DR   Pfam; PF17779; NOD2_WH; 1.
DR   Pfam; PF02758; PYRIN; 1.
DR   SMART; SM00368; LRR_RI; 3.
DR   SMART; SM01289; PYRIN; 1.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF52047; RNI-like; 1.
DR   PROSITE; PS50824; DAPIN; 1.
DR   PROSITE; PS50837; NACHT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane; Cytoplasm;
KW   Immunity; Inflammasome; Inflammatory response; Innate immunity;
KW   Leucine-rich repeat; Membrane; Nucleotide-binding; Nucleus;
KW   Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN           1..892
FT                   /note="NACHT, LRR and PYD domains-containing protein 6"
FT                   /id="PRO_0000080892"
FT   DOMAIN          1..103
FT                   /note="Pyrin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00061"
FT   DOMAIN          196..513
FT                   /note="NACHT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136"
FT   REPEAT          462..487
FT                   /note="LRR 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          727..747
FT                   /note="LRR 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          755..778
FT                   /note="LRR 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          811..834
FT                   /note="LRR 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          845..868
FT                   /note="LRR 5"
FT                   /evidence="ECO:0000255"
FT   REGION          158..181
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          352..356
FT                   /note="Disordered"
FT                   /evidence="ECO:0000269|PubMed:34678144"
FT   REGION          590..614
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        166..181
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         202..209
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136"
FT   VAR_SEQ         702
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054400"
FT   VARIANT         163
FT                   /note="M -> L (in dbSNP:rs6421985)"
FT                   /evidence="ECO:0000269|PubMed:12019269,
FT                   ECO:0000269|PubMed:12563287, ECO:0000269|PubMed:14702039"
FT                   /id="VAR_058968"
FT   VARIANT         361
FT                   /note="Y -> F (in dbSNP:rs7482965)"
FT                   /evidence="ECO:0000269|PubMed:12019269,
FT                   ECO:0000269|PubMed:12563287, ECO:0000269|PubMed:14702039"
FT                   /id="VAR_058969"
FT   VARIANT         713
FT                   /note="A -> V (in dbSNP:rs966612159)"
FT                   /evidence="ECO:0000269|PubMed:26282398"
FT                   /id="VAR_079497"
FT   MUTAGEN         21
FT                   /note="L->R: Decreased formation of an inflammasome
FT                   filament."
FT                   /evidence="ECO:0000269|PubMed:30674671"
FT   MUTAGEN         23
FT                   /note="L->R: Decreased formation of an inflammasome
FT                   filament. Decreased ability to promote PYCARD/ASC
FT                   polymerization."
FT                   /evidence="ECO:0000269|PubMed:30674671"
FT   MUTAGEN         27..28
FT                   /note="EE->RR: Abolished formation of an inflammasome
FT                   filament."
FT                   /evidence="ECO:0000269|PubMed:30674671"
FT   MUTAGEN         39
FT                   /note="H->R: Decreased formation of an inflammasome
FT                   filament. Abolished ability to promote PYCARD/ASC
FT                   polymerization."
FT                   /evidence="ECO:0000269|PubMed:30674671"
FT   MUTAGEN         42
FT                   /note="R->E: Abolished formation of an inflammasome
FT                   filament."
FT                   /evidence="ECO:0000269|PubMed:30674671"
FT   MUTAGEN         53
FT                   /note="W->E: Abolished formation of an inflammasome
FT                   filament."
FT                   /evidence="ECO:0000269|PubMed:30674671"
FT   MUTAGEN         53
FT                   /note="W->F: Does not affect formation of an inflammasome
FT                   filament."
FT                   /evidence="ECO:0000269|PubMed:30674671"
FT   MUTAGEN         71
FT                   /note="F->R: Does not prevent formation of an inflammasome
FT                   filament."
FT                   /evidence="ECO:0000269|PubMed:30674671"
FT   MUTAGEN         87
FT                   /note="R->D: Does not prevent formation of an inflammasome
FT                   filament."
FT                   /evidence="ECO:0000269|PubMed:30674671"
FT   MUTAGEN         352..356
FT                   /note="KDKKK->ADAAA: Impaired formation of liquid-liquid
FT                   phase separation (LLPS)."
FT                   /evidence="ECO:0000269|PubMed:34678144"
FT   HELIX           14..27
FT                   /evidence="ECO:0007829|PDB:6NDJ"
FT   HELIX           31..41
FT                   /evidence="ECO:0007829|PDB:6NDJ"
FT   HELIX           46..48
FT                   /evidence="ECO:0007829|PDB:6NDJ"
FT   HELIX           56..58
FT                   /evidence="ECO:0007829|PDB:6NDJ"
FT   HELIX           61..72
FT                   /evidence="ECO:0007829|PDB:6NDJ"
FT   HELIX           74..85
FT                   /evidence="ECO:0007829|PDB:6NDJ"
SQ   SEQUENCE   892 AA;  98768 MW;  A987FDACE6448C6A CRC64;
     MDQPEAPCSS TGPRLAVARE LLLAALEELS QEQLKRFRHK LRDVGPDGRS IPWGRLERAD
     AVDLAEQLAQ FYGPEPALEV ARKTLKRADA RDVAAQLQER RLQRLGLGSG TLLSVSEYKK
     KYREHVLQLH ARVKERNARS VKITKRFTKL LIAPESAAPE EAMGPAEEPE PGRARRSDTH
     TFNRLFRRDE EGRRPLTVVL QGPAGIGKTM AAKKILYDWA AGKLYQGQVD FAFFMPCGEL
     LERPGTRSLA DLILDQCPDR GAPVPQMLAQ PQRLLFILDG ADELPALGGP EAAPCTDPFE
     AASGARVLGG LLSKALLPTA LLLVTTRAAA PGRLQGRLCS PQCAEVRGFS DKDKKKYFYK
     YFRDERRAER AYRFVKENET LFALCFVPFV CWIVCTVLRQ QLELGRDLSR TSKTTTSVYL
     LFITSVLSSA PVADGPRLQG DLRNLCRLAR EGVLGRRAQF AEKELEQLEL RGSKVQTLFL
     SKKELPGVLE TEVTYQFIDQ SFQEFLAALS YLLEDGGVPR TAAGGVGTLL RGDAQPHSHL
     VLTTRFLFGL LSAERMRDIE RHFGCMVSER VKQEALRWVQ GQGQGCPGVA PEVTEGAKGL
     EDTEEPEEEE EGEEPNYPLE LLYCLYETQE DAFVRQALCR FPELALQRVR FCRMDVAVLS
     YCVRCCPAGQ ALRLISCRLV AAQEKKKKSL GKRLQASLGG GSSSQGTTKQ LPASLLHPLF
     QAMTDPLCHL SSLTLSHCKL PDAVCRDLSE ALRAAPALTE LGLLHNRLSE AGLRMLSEGL
     AWPQCRVQTV RVQLPDPQRG LQYLVGMLRQ SPALTTLDLS GCQLPAPMVT YLCAVLQHQG
     CGLQTLSLAS VELSEQSLQE LQAVKRAKPD LVITHPALDG HPQPPKELIS TF
//
